Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Biological Psychiatry

Volumn 61, Issue 12, 2007, Pages 1380-1387

  Spencer, Thomas J ^a   Adler, Lenard A ^b   McGough, James J ^c   Muniz, Rafael ^d   Jiang, Hai ^d   Pestreich, Linda ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ADHD; adults; capsules; d MPH ER; efficacy; safety

Indexed keywords

DEXMETHYLPHENIDATE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EVALUATION; EXTENDED RELEASE FORMULATION; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 34249791788     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.07.032     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (2000), American Psychiatric Association, Washington, DC Text Revision
2. Barkley R.A. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (1990), Guilford Press, New York
3. Biederman J. Attention-deficit/hyperactivity disorder: A life-span perspective. J Clin Psychiatry 59 (1998) 4-16
4. Biederman J., Spencer T.J., Wilens T.E., Weisler R.H., Read S.C., Tulloch S.J., and SLI381.304 study group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10 12 Suppl 20 (2005) 16-25
5. Conners C.K., Erhardt D., and Sparrow E.P. Conner's Adult ADHD Rating Scales (CAARS) Technical Manual (1999), Multi-Health Systems Inc, North Tonawanda, NY
6. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl) 160 (2002) 92-98
7. Ding Y.S., Fowler J.S., Volkow N.D., Dewey S.L., Wang G.J., Logan J., et al. Chiral drugs: Comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131 (1997) 71-78
8. DuPaul G., Power T., Anastopoulos A., and Reid R. ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation (1998), Guilford Press, New York
9. Endicott J., Nee J., Harrison W., and Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 29 (1993) 321-326
10. Faraone S.V. Understanding the effect size of ADHD medications: Implications for clinical care (2003). http://www.medscape.com/viewarticle/461543 Available at: http://www.medscape.com/viewarticle/461543. Accessed April 3, 2006.
11. Faraone S.V., Biederman J., Spencer T., Wilens T., Seidman L.J., Mick E., et al. Attention-deficit/hyperactivity disorder in adults: An overview. Biol Psychiatry 48 (2000) 9-20
12. Faraone S.V., Spencer T., Aleardi M., Pagano C., and Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24 (2004) 24-29
13. Goodman D.W., Ginsberg L., Weisler R.H., and Cutler A.J. An interim analysis of the quality of life, effectiveness, safety, and tolerability (Q.U.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10 12 Suppl 20 (2005) 26-34
14. Gualtieri C.T., Ondrusek M.G., and Finley C. Attention deficit disorders in adults. Clin Neuropharmacol 8 (1985) 343-356
15. Guy W. 028 CGI Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (1976), U.S. Department of Health, Education and Welfare, National Institute Mental Health, Bethesda, MD 217-222 NIMH publication DHEW (Adm) 76-338
16. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika 75 (1988) 800-803
17. Keating G.M., and Figgitt D.P. Dexmethylphenidate. Drugs 62 (2002) 1899-1904
18. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., et al. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry 163 (2006) 716-723
19. Kimko H.C., Cross J.T., and Abernethy D.R. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37 (1999) 457-470
20. Mannuzza S., Klein R.G., Bessler A., Malloy P., and LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50 (1993) 565-576
21. Mick E., Spencer T.J., Faraone S.V., Zhang H., and Biederman J. Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire in adults with ADHD (2006) Poster presented at the 159th Annual Meeting of the American Psychiatric Association, May 20-25, 2006.
22. Quinn D., Wigal S., Swanson J., Hirsch S., Ottolini Y., Dariani M., et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43 (2004) 1422-1429
23. Spencer T., Biederman J., Wilens T., Doyle R., Surman C., Prince J., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 456-463
24. Spencer T., Biederman J., Wilens T., and Faraone S.V. Is attention-deficit hyperactivity disorder in adults a valid disorder?. Harv Rev Psychiatry 1 (1994) 326-335
25. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155 (1998) 693-695
26. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon J.S., and Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52 (1995) 434-443
27. Stein M.A., Sarampote C.S., Waldman I.D., Robb A.S., Conlon C., Pearl P.L., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112 (2003) e404
28. Swanson J.M., Wigal S., Greenhill L.L., Browne R., Waslik B., Lerner M., et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37 (1998) 519-526
29. Weiss G., Hechtman L., Milroy T., and Perlman T. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24 (1985) 211-220
30. Wender P.H., Reimherr F.W., Wood D., and Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142 (1985) 547-552
31. Wilens T.E., Faraone S.V., and Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 292 (2004) 619-623